GlassScriptPhysician profile
Sandhya H Desai
NPI 1528082872
$2,135.99
in general payments reported to CMS, 2019-2025
15 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $254 · 2021: $310 · 2022: $134 · 2023: $158 · 2024: $303 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.68 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $290.32 | 2019-2025 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $228.59 | 2019-2021 | |
| Genzyme Corporation | $165.55 | 2019-2024 | |
| Pfizer INC. | $158.90 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $134.21 | 2019 | |
| Csl Behring | $123.92 | 2019-2023 | Hizentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.36 | 2024-2025 | Xifaxan |
| Amgen INC. | $80.22 | 2022-2024 | Tezspire |
| Optinose US, INC. | $42.42 | 2019-2024 | |
| Covis Pharma Gmbh | $37.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.74 | 2020 | |
| Bio Products Laboratory USA, INC. | $32.18 | 2021-2022 | |
| Urgo Medical North America, LLC | $18.75 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Genentech USA, INC. | $17.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.